Voluntary announcement topline data from the phase ii clinical trial in china of LP-005 for the treatment of pnh
Filed with HKEX · Stock code 1779 ·
6ix is reading this filing.
View original source (HKEXnews)LongBio Pharma (Suzhou) Co., Ltd. on 6ix
Earlier from LongBio Pharma (Suzhou)
- Form of proxy for use by shareholders at the 2026 EGM (or any adjournment thereof) to be held at 4: 00 p.m. on Friday, October 30, 2026
- Notice of extraordinary general meeting
- Proposed amendments to the articles of association and notice of extraordinary general meeting
- Proposed amendments to the articles of association
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow LongBio Pharma (Suzhou) into a list and get an email when it puts out news.
Follow LongBio Pharma (Suzhou)